Identification of Low Molecular Weight Pyroglutamate Aβ Oligomers in Alzheimer Disease

Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy

Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works

Alzheimer's Disease: Genes, Proteins, and Therapy

Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063 · see citing works

Amyloid plaque core protein in Alzheimer disease and Down syndrome.

Masters, C. L., Simms, G., Weinman, N. A., Multhaup, G., McDonald, B. L., & Beyreuther, K. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.12.4245 · Cited by 4,431 · see citing works

Alzheimer's Disease Is a Synaptic Failure

Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420 · see citing works

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291 · see citing works

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

Kayed, R., Head, E., Thompson, J. L., McIntire, T. M., Milton, S. C., Cotman, C. W., & Glabe, C. G. (2003) · Science · doi:10.1126/science.1079469 · Cited by 4,064 · see citing works

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685 · see citing works

Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation

Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works

Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,677 · see citing works

Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway

Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · see citing works

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works

Correlation Between Elevated Levels of Amyloid β-Peptide in the Brain and Cognitive Decline

Näslund, J. (2000) · JAMA · doi:10.1001/jama.283.12.1571 · Cited by 1,268 · see citing works

Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · see citing works

Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

Gong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · see citing works

Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?

Klein, W. (2001) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01749-5 · Cited by 989 · see citing works

The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease

Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · see citing works

Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · see citing works

Structure–neurotoxicity relationships of amyloid β-protein oligomers

Ono, K., Condron, M. M., & Teplow, D. B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905127106 · Cited by 774 · see citing works

Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Aβ aggregation in the 5XFAD mouse model of Alzheimer's disease.

Jawhar, S., Trawicka, A., Jenneckens, C., Bayer, T. A., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.027 · Cited by 623 · see citing works

Dominant and differential deposition of distinct β-amyloid peptide species, AβN3(pE), in senile plaques

Saido, T. C., Iwatsubo, T., Mann, D. M. A., Shimada, H., Ihara, Y., & Kawashima, S. (1995) · Neuron · doi:10.1016/0896-6273(95)90301-1 · Cited by 587 · see citing works

Aβ toxicity in Alzheimer’s disease: globular oligomers (ADDLs) as new vaccine and drug targets

Klein, W. L. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(02)00050-5 · Cited by 541 · see citing works

The Oligomerization of Amyloid β-Protein Begins Intracellularly in Cells Derived from Human Brain

Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B., & Selkoe, D. J. (2000) · Biochemistry · doi:10.1021/bi001048s · Cited by 502 · see citing works

Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo

Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489 · see citing works

Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.

Mori, H., Takio, K., OGAWARA, M., & Selkoe, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41896-0 · Cited by 481 · see citing works

Isolation of Low‐Molecular‐Weight Proteins from Amyloid Plaque Fibers in Alzheimer's Disease

Selkoe, D. J., Abraham, C. R., Podlisny, M. B., & Duffy, L. K. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb08501.x · Cited by 450 · see citing works

Oligomerization of Alzheimer's β-Amyloid within Processes and Synapses of Cultured Neurons and Brain

Takahashi, R. H., Almeida, C. G., Kearney, P. F., Yu, F., Lin, M. T., Milner, T. A., & Gouras, G. K. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5167-03.2004 · Cited by 445 · see citing works

Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411 · see citing works

Massive CA1/2 Neuronal Loss with Intraneuronal and N-Terminal Truncated Aβ42 Accumulation in a Novel Alzheimer Transgenic Model

Casas, C., Sergeant, N., Itier, J.-M., Blanchard, V., Wirths, O., van der Kolk, N., Vingtdeux, V., van de Steeg, E., Ret, G., Canton, T., et al. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63388-3 · Cited by 400 · see citing works

A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss <i>In Vivo</i>

Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5825-09.2010 · Cited by 396 · see citing works

Huntingtin aggregates may not predict neuronal death in Huntington's disease

Kuemmerle, S., Gutekunst, C., Klein, A., Li, X., Li, S.-H., Beal, M. F., Hersch, S. M., & Ferrante, R. J. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199912)46:6 · Cited by 387 · see citing works

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., et al. (2008) · Nature Medicine · doi:10.1038/nm.1872 · Cited by 357 · see citing works

A modified β‐amyloid hypothesis: intraneuronal accumulation of the β‐amyloid peptide – the first step of a fatal cascade

Wirths, O., Multhaup, G., & Bayer, T. A. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02737.x · Cited by 349 · see citing works

Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

Klyubin, I., Betts, V., Welzel, A. T., Blennow, K., Zetterberg, H., Wallin, A., Lemere, C. A., Cullen, W. K., Peng, Y., Wisniewski, T., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.5161-07.2008 · Cited by 321 · see citing works

High‐molecular‐weight β‐amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients

Fukumoto, H., Tokuda, T., Kasai, T., Ishigami, N., Hidaka, H., Kondo, M., Allsop, D., & Nakagawa, M. (2010) · The FASEB Journal · doi:10.1096/fj.09-150359 · Cited by 264 · see citing works

The Arctic Alzheimer mutation facilitates early intraneuronal Aβ aggregation and senile plaque formation in transgenic mice

Lord, A., Kalimo, H., Eckman, C., Zhang, X.-Q., Lannfelt, L., & Nilsson, L. N. G. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.12.007 · Cited by 260 · see citing works

Active and passive immunotherapy for neurodegenerative disorders

Brody, D. L., & Holtzman, D. M. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125529 · Cited by 250 · see citing works

β-Amyloid Immunotherapy Prevents Synaptic Degeneration in a Mouse Model of Alzheimer's Disease

Buttini, M., Masliah, E., Barbour, R., Grajeda, H., Motter, R., Johnson-Wood, K., Khan, K., Seubert, P., Freedman, S., Schenk, D., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1697-05.2005 · Cited by 176 · see citing works

Intraneuronal pyroglutamate-Abeta 3–42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model

Wirths, O., Breyhan, H., Cynis, H., Schilling, S., Demuth, H.-U., & Bayer, T. A. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0557-5 · Cited by 174 · see citing works

Isolation and Partial Characterization of Neurofibrillary Tangles and Amyloid Plaque Core in Alzheimerʼs Disease

Gorevic, P. D., Goñi, F., Pons‐Estel, B. A., Álvarez, F., Peress, N. S., & Frangione, B. (1986) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-198611000-00004 · Cited by 124 · see citing works

Amyloidogenic Processing of Amyloid Precursor Protein: Evidence of a Pivotal Role of Glutaminyl Cyclase in Generation of Pyroglutamate-Modified Amyloid-β

Cynis, H., Scheel, E., Saido, T. C., Schilling, S., & Demuth, H. (2008) · Biochemistry · doi:10.1021/bi800250p · Cited by 117 · see citing works

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases

Wirths, O., Bethge, T., Marcello, A., Harmeier, A., Jawhar, S., Lucassen, P. J., Multhaup, G., Brody, D. L., Esparza, T., Ingelsson, M., et al. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-009-0314-x · Cited by 106 · see citing works

Deficits in working memory and motor performance in the APP/PS1ki mouse model for Alzheimer's disease

Wirths, O., Breyhan, H., Schäfer, S., Roth, C., & Bayer, T. A. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.12.004 · Cited by 97 · see citing works

Role of Amyloid- Glycine 33 in Oligomerization, Toxicity, and Neuronal Plasticity

Harmeier, A., Wozny, C., Rost, B. R., Munter, L. M., Hua, H., Georgiev, O., Beyermann, M., Hildebrand, P. W., Weise, C., Schaffner, W., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1336-09.2009 · Cited by 94 · see citing works

Amyloid‐β protofibril levels correlate with spatial learning in Arctic Alzheimer’s disease transgenic mice

Lord, A., Englund, H., Söderberg, L., Tucker, S. M., Clausen, F., Hillered, L., Gordon, M. N., Morgan, D., Lannfelt, L., Pettersson, F. E., et al. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06836.x · Cited by 91 · see citing works

Amyloid &amp;#946;-Peptide: The Inside Story

Tseng, B., Kitazawa, M., & LaFerla, F. (2004) · Current Alzheimer Research · doi:10.2174/1567205043332045 · Cited by 72 · see citing works

Passive Immunization against β-Amyloid Peptide Protects Central Nervous System (CNS) Neurons from Increased Vulnerability Associated with an Alzheimer’s Disease-causing Mutation

Mohajeri, M. H., Saini, K., Schultz, J. G., Wollmer, M. A., Höck, C., & Nitsch, R. M. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203193200 · Cited by 59 · see citing works

Reduced levels of IgM autoantibodies against N-truncated pyroglutamate Aβ in plasma of patients with Alzheimer's disease

Marcello, A., Wirths, O., Schneider-Axmann, T., Degerman-Gunnarsson, M., Lannfelt, L., & Bayer, T. A. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.011 · Cited by 29 · see citing works

Genetically modified PC12 brain grafts: Survivability and inducible nerve growth factor expression

Rohrer, D. C. (1996) · Cell Transplantation · doi:10.1016/0963-6897(95)02023-3 · Cited by 19 · see citing works

Genetically Modified Pc 12 Brain Grafts: Survivability and Inducible Nerve Growth Factor Expression

Rohrer, D. C., Nilaver, G., Nipper, V. J., et al. (1996) · Cell Transplantation · doi:10.1177/096368979600500111 · Cited by 5 · see citing works

Neuron loss in the 5XFAD mouse model of Alzheimer’s disease correlates with intraneuronal Aβ42 accumulation and Caspase-3 activation

Eimer, W. A., & Vassar, R. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-2 · Cited by 425 · see citing works

Oligomeric Intermediates in Amyloid Formation: Structure Determination and Mechanisms of Toxicity

Fändrich, M. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.01.006 · Cited by 339 · see citing works

Copper and Oxidative Stress in the Pathogenesis of Alzheimer’s Disease

Eskici, G., & Axelsen, P. H. (2012) · Biochemistry · doi:10.1021/bi3006169 · Cited by 288 · see citing works

Amyloid β-protein oligomers and Alzheimer’s disease

Hayden, E. Y., & Teplow, D. B. (2013) · Alzheimer's Research &amp; Therapy · doi:10.1186/alzrt226 · Cited by 276 · see citing works

Pyroglutamate Amyloid-β (Aβ): A Hatchet Man in Alzheimer Disease

Jawhar, S., Wirths, O., & Bayer, T. A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.r111.288308 · Cited by 220 · see citing works

Immunotherapy for Alzheimer’s disease: hoops and hurdles

Lemere, C. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-36 · Cited by 196 · see citing works

Effects of in vivo conditions on amyloid aggregation

Owen, M. C., Gnutt, D., Gao, M., Wärmländer, S. K. T. S., Jarvet, J., Gräslund, A., Winter, R., Ebbinghaus, S., & Strodel, B. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00034d · Cited by 179 · see citing works

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer’s disease

Bayer, T. A., & Wirths, O. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1287-x · Cited by 168 · see citing works

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease

Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 156 · see citing works

Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease

Bhattacharya, S., Haertel, C., Maelicke, A., & Montag, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089454 · Cited by 142 · see citing works

Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?

Bayer, T. A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.007 · Cited by 141 · see citing works

Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease

Webster, S. J., Bachstetter, A. D., & Eldik, L. J. V. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt182 · Cited by 140 · see citing works

BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology

Koelsch, G. (2017) · Molecules · doi:10.3390/molecules22101723 · Cited by 125 · see citing works

APP/Aβ structural diversity and Alzheimer's disease pathogenesis

Roher, A. E., Kokjohn, T. A., Clarke, S. G., Sierks, M. R., Maarouf, C. L., Serrano, G. E., Sabbagh, M., & Beach, T. G. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.08.007 · Cited by 121 · see citing works

Glutaminyl Cyclase in Human Cortex: Correlation with (pGlu)-Amyloid-β Load and Cognitive Decline in Alzheimer's Disease

Morawski, M., Schilling, S., Kreuzberger, M., Waniek, A., Jäger, C., Koch, B. M., Cynis, H., Kehlen, A., Arendt, T., Hartlage‐Rübsamen, M., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131535 · Cited by 114 · see citing works

Phosphorylation of the amyloid β-peptide at Ser26 stabilizes oligomeric assembly and increases neurotoxicity

Kumar, S., Wirths, O., Stüber, K., Wunderlich, P., Koch, P., Theil, S., Rezaei‐Ghaleh, N., Zweckstetter, M., Bayer, T. A., Brüstle, O., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1546-0 · Cited by 106 · see citing works

Amyloid-β Oligomers in Cerebrospinal Fluid are Associated with Cognitive Decline in Patients with Alzheimer's Disease

Santos, A. N., Ewers, M., Minthon, L., Simm, A., Silber, R., Blennow, K., Prvulovic, D., Hansson, O., & Hampel, H. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-111361 · Cited by 101 · see citing works

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease

Bayer, T. A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01409-2 · Cited by 98 · see citing works

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease

Moro, M. L., Phillips, A. S., Gaimster, K., Paul, C., Mudher, A. K., Nicoll, J. A. R., & Boche, D. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0505-x · Cited by 95 · see citing works

Hyperphosphorylated tau in young and middle-aged subjects

El‐Obeid, A., Soininen, H. S., & Alafuzoff, I. I. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0906-z · Cited by 92 · see citing works

Passive Immunization against Pyroglutamate-3 Amyloid-β Reduces Plaque Burden in Alzheimer-Like Transgenic Mice: A Pilot Study

Frost, J. L., Liu, B., Kleinschmidt, M., Schilling, S., Demuth, H., & Lemere, C. A. (2012) · Neurodegenerative Diseases · doi:10.1159/000335913 · Cited by 82 · see citing works

Behaviour Hallmarks in Alzheimer’s Disease 5xFAD Mouse Model

Pádua, M. S., Guil‐Guerrero, J. L., & Lopes, P. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126766 · Cited by 87 · see citing works

Synaptic deficits in layer 5 neurons precede overt structural decay in 5xFAD mice

Buskila, Y., Crowe, S. E., & Ellis-Davies, G. C. R. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.09.016 · Cited by 77 · see citing works

Pyroglutamate Amyloid β (Aβ) Aggravates Behavioral Deficits in Transgenic Amyloid Mouse Model for Alzheimer Disease

Wittnam, J. L., Portelius, E., Zetterberg, H., Gustavsson, M. K., Schilling, S., Koch, B. C. P., Demuth, H., Blennow, K., Wirths, O., & Bayer, T. A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.308601 · Cited by 77 · see citing works

Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice

Huang, H., Nie, S., Cao, M., Marshall, C., Gao, J., Xiao, N., Hu, G., & Xiao, M. (2016) · AGE · doi:10.1007/s11357-016-9929-7 · Cited by 75 · see citing works

Methods for Analysis of Amyloid-β Aggregates

Bruggink, K. A., Müller, M., Kuiperij, H. B., & Verbeek, M. M. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111421 · Cited by 74 · see citing works

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncated Abeta in sporadic Alzheimer disease cases and mouse models

Bouter, Y., López‐Noguerola, J. S., Tucholla, P., Crespi, G. A. N., Parker, M. W., Wiltfang, J., Miles, L. A., & Bayer, T. A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1489-x · Cited by 74 · see citing works

Endothelial LRP1 – A Potential Target for the Treatment of Alzheimer’s Disease

Storck, S. E., & Pietrzik, C. U. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2267-3 · Cited by 69 · see citing works

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy

Pérez-Garmendia, R., & Gevorkian, G. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311050004 · Cited by 65 · see citing works

An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice

Frost, J. L., Liu, B., Rahfeld, J., Kleinschmidt, M., O’Nuallain, B., Le, K. X., Lues, I., Caldarone, B. J., Schilling, S., Demuth, H., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.021 · Cited by 63 · see citing works

Intracellular accumulation of aggregated pyroglutamate amyloid beta: convergence of aging and Aβ pathology at the lysosome

Kimpe, L. D., van Haastert, E. S., Kaminari, A., Zwart, R., Rutjes, H., Hoozemans, J. J. M., & Scheper, W. (2012) · AGE · doi:10.1007/s11357-012-9403-0 · Cited by 60 · see citing works

N-truncated Abeta starting with position four: Early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody

Antonios, G., Saiepour, N., Bouter, Y., Richard, B. C., Paetau, A., Verkkoniemi-Ahola, A., Lannfelt, L., Ingelsson, M., Kovacs, G. G., Pillot, T., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-56 · Cited by 53 · see citing works

Enhanced Fibril Fragmentation of N‐Terminally Truncated and Pyroglutamyl‐Modified Aβ Peptides

Wulff, M., Baumann, M., Thümmler, A., Yadav, J. K., Heinrich, L., Knüpfer, U., Schlenzig, D., Schierhorn, A., Rahfeld, J., Horn, U., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511099 · Cited by 53 · see citing works

Differential toxicity, conformation and morphology of typical initial aggregation states of Aβ1-42 and Aβpy3-42 beta-amyloids

Galante, D., Corsaro, A., Florio, T., Vella, S., Pagano, A., Sbrana, F., Vassalli, M., Perico, A., & D’Arrigo, C. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.08.010 · Cited by 51 · see citing works

Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer’s-like mice

Crehan, H., Liu, B., Kleinschmidt, M., Rahfeld, J., Le, K. X., Caldarone, B. J., Frost, J. L., Hettmann, T., Hutter‐Paier, B., O’Nuallain, B., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0579-8 · Cited by 48 · see citing works

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges

Cynis, H., Frost, J. L., Crehan, H., & Lemere, C. A. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0115-2 · Cited by 48 · see citing works

Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core

Sullivan, C. P., Berg, E. A., Elliott-Bryant, R., Fishman, J. B., McKee, A. C., Morin, P. J., Shia, M. A., & Fine, R. E. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.09.071 · Cited by 46 · see citing works

Emerging roles of N- and C-terminally truncated Aβ species in Alzheimer’s disease

Wirths, O., & Zampar, S. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1702972 · Cited by 44 · see citing works

Human glutaminyl cyclase: Structure, function, inhibitors and involvement in Alzheimer’s disease

Dileep, K. V., & Zhang, K. Y. J. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104342 · Cited by 43 · see citing works

Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?

Bayer, T. A., & Wirths, O. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390857 · Cited by 41 · see citing works

Protein engineering to stabilize soluble amyloid β‐protein aggregates for structural and functional studies

Härd, T. (2011) · FEBS Journal · doi:10.1111/j.1742-4658.2011.08295.x · Cited by 40 · see citing works

Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease

Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 39 · see citing works

pGluAβ increases accumulation of Aβ in vivo and exacerbates its toxicity

Sofola-Adesakin, O., Khericha, M., Snoeren, I., Tsuda, L., & Partridge, L. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0380-x · Cited by 37 · see citing works

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Xu, C., Wang, Y., & Wu, H. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00325 · Cited by 36 · see citing works

Structural Analysis and Aggregation Propensity of Pyroglutamate Aβ(3-40) in Aqueous Trifluoroethanol

Dammers, C., Gremer, L., Reiß, K., Klein, A. N., Neudecker, P., Hartmann, R., Sun, N., Demuth, H., Schwarten, M., & Willbold, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143647 · Cited by 31 · see citing works

Aβ38 in the Brains of Patients with Sporadic and Familial Alzheimer's Disease and Transgenic Mouse Models

Reinert, J., Martens, H., Hüttenrauch, M., Kolbow, T., Lannfelt, L., Ingelsson, M., Paetau, A. E., Verkkoniemi‐Ahola, A., Bayer, T. A., & Wirths, O. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131373 · Cited by 33 · see citing works

Disturbed Ca2+ Homeostasis Increases Glutaminyl Cyclase Expression; Connecting Two Early Pathogenic Events in Alzheimer’s Disease In Vitro

Kimpe, L. D., Bennis, A., Zwart, R., van Haastert, E. S., Hoozemans, J. J. M., & Scheper, W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044674 · Cited by 32 · see citing works

Pyroglutamate-Modified Amyloid-β Protein Demonstrates Similar Properties in an Alzheimer's Disease Familial Mutant Knock-In Mouse and Alzheimer's Disease Brain

Wu, G., Miller, R. A., Connolly, B., Marcus, J., Renger, J. J., & Savage, M. J. (2013) · Neurodegenerative Diseases · doi:10.1159/000353634 · Cited by 31 · see citing works

Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease

Pivtoraiko, V. N., Abrahamson, E. E., Leurgans, S. E., DeKosky, S. T., Mufson, E. J., & Ikonomović, M. D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.021 · Cited by 31 · see citing works

Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer’s disease with reduced complement activation

Hettmann, T., Gillies, S. D., Kleinschmidt, M., Piechotta, A., Makioka, K., Lemere, C. A., Schilling, S., Rahfeld, J., & Lues, I. (2020) · Scientific Reports · doi:10.1038/s41598-020-60319-5 · Cited by 29 · see citing works

Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy

Piechotta, A., Parthier, C., Kleinschmidt, M., Gnoth, K., Pillot, T., Lues, I., Demuth, H., Schilling, S., Rahfeld, J., & Stubbs, M. T. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.777839 · Cited by 28 · see citing works

Alzheimer's disease biomarkers: correspondence between human studies and animal models

Sabbagh, J. J., Kinney, J. W., & Cummings, J. L. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.04.010 · Cited by 27 · see citing works

AβPP Accumulation and/or Intraneuronal Amyloid-β Accumulation? The 3xTg-AD Mouse Model Revisited

Wirths, O., Dins, A., & Bayer, T. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111529 · Cited by 26 · see citing works

Pyroglutamylated Amyloid-β Peptide Reverses Cross β-Sheets by a Prion-Like Mechanism

Matos, J. O., Goldblatt, G., Jeon, J., Chen, B., & Tatulian, S. A. (2014) · The Journal of Physical Chemistry B · doi:10.1021/jp412743s · Cited by 25 · see citing works

Alzheimer’s Disease—A Panorama Glimpse

Zhao, L. N., Lu, L., Chew, L. Y., & Mu, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms150712631 · Cited by 23 · see citing works

Current viral-mediated gene transfer research for treatment of Alzheimer’s disease

Sasmita, A. O. (2018) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2018.1523521 · Cited by 23 · see citing works

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy

Dammers, C., Gremer, L., Neudecker, P., Demuth, H., Schwarten, M., & Willbold, D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0139710 · Cited by 22 · see citing works

Oligomeric Pyroglutamate Amyloid-β is Present in Microglia and a Subfraction of Vessels in Patients with Alzheimer's Disease: Implications for Immunotherapy

Wirths, O., Hillmann, A., Pradier, L., Härtig, W., & Bayer, T. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121945 · Cited by 21 · see citing works

Unmodified and pyroglutamylated amyloid β peptides form hypertoxic hetero‐oligomers of unique secondary structure

Goldblatt, G., Cilenti, L., Matos, J. O., Lee, B., Ciaffone, N., Wang, Q. X., Tétard, L., Teter, K., & Tatulian, S. A. (2017) · FEBS Journal · doi:10.1111/febs.14058 · Cited by 21 · see citing works

Abundant pyroglutamate-modified ABri and ADan peptides in extracellular and vascular amyloid deposits in familial British and Danish dementias

Saul, A., Lashley, T., Révész, T., Holton, J. L., Ghiso, J. A., Coomaraswamy, J., & Wirths, O. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.014 · Cited by 21 · see citing works

Mouse strain and brain region‐specific expression of the glutaminyl cyclases QC and isoQC

Höfling, C., Indrischek, H., Höpcke, T., Waniek, A., Cynis, H., Koch, B. M., Schilling, S., Morawski, M., Demuth, H., Roßner, S., et al. (2014) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2014.05.008 · Cited by 20 · see citing works

Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation

Hartlage‐Rübsamen, M., Bluhm, A., Piechotta, A., Linnert, M., Rahfeld, J., Demuth, H., Lues, I., Kuhn, P., Lichtenthaler, S. F., Roßner, S., et al. (2018) · Molecules · doi:10.3390/molecules23040924 · Cited by 19 · see citing works

Correlation of pyroglutamate amyloid β and ptau Ser202/Thr205 levels in Alzheimer’s disease and related murine models

Neddens, J., Daurer, M., Flunkert, S., Beutl, K., Loeffler, T., Walker, L., Attems, J., & Hutter‐Paier, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235543 · Cited by 20 · see citing works

Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates

Venkataramani, V., Wirths, O., Budka, H., Härtig, W., Kovács, G. G., & Bayer, T. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111379 · Cited by 17 · see citing works

The structure of tyrosine-10 favors ionic conductance of Alzheimer’s disease-associated full-length amyloid-β channels

Karkisaval, A. G., Hassan, R., Nguyen, A., Balster, B., Abedin, F., Lal, R., & Tatulian, S. A. (2024) · Nature Communications · doi:10.1038/s41467-023-43821-y · Cited by 16 · see citing works

Cathepsin B-A Neuronal Death Mediator in Alzheimer’s Disease Leading to Neurodegeneration

Singh, S. K., Sharma, A., Swetha, R., Bajad, N. G., Ganeshpurkar, A., Singh, R., & Kumar, A. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522666220214095859 · Cited by 16 · see citing works

I716F AβPP Mutation Associates with the Deposition of Oligomeric Pyroglutamate Amyloid-β and α-Synucleinopathy with Lewy Bodies

Berger–Sieczkowski, E., Milenković, I., Venkataramani, V., Giera, R., Ströbel, T., Höftberger, R., Liberski, P. P., Auff, E., Wirths, O., Bayer, T. A., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141524 · Cited by 15 · see citing works

Novel Phosphorylation-State Specific Antibodies Reveal Differential Deposition of Ser26 Phosphorylated Aβ Species in a Mouse Model of Alzheimer’s Disease

Kumar, S., Kapadia, A., Theil, S., Joshi, P., Riffel, F., Heneka, M. T., & Walter, J. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.619639 · Cited by 15 · see citing works

Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective

Li, X., Quan, M., Wei, Y., Wang, W., Xu, L., Wang, Q., & Jia, J. (2023) · Science China Life Sciences · doi:10.1007/s11427-022-2357-x · Cited by 14 · see citing works

Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer’s Disease Model Mice

Gao, L., Hu, Z., Chen, P., Sun, Z., Chen, Y., Zhao, Y., & Li, Y. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00336 · Cited by 11 · see citing works

A Modification-Specific Peptide-Based immunization Approach Using CRM197 Carrier Protein: Development of a Selective Vaccine Against Pyroglutamate Aβ Peptides

Vingtdeux, V., Zhao, H., Chandakkar, P., Acker, C. M., Davies, P., & Marambaud, P. (2016) · Molecular Medicine · doi:10.2119/molmed.2016.00218 · Cited by 11 · see citing works

N-Terminally Truncated Aß Peptide Variants in Alzheimer’s Disease

Wirths, O., Zampar, S., & Weggen, S. (2019) · Codon Publications eBooks · doi:10.15586/alzheimersdisease.2019.ch7 · Cited by 11 · see citing works

β-Amyloids and Immune Responses Associated with Alzheimer’s Disease

Kolobova, E. A., Petrushanko, I. Y., Mitkevich, V. A., Makarov, A. А., & Grigorova, I. (2024) · Cells · doi:10.3390/cells13191624 · Cited by 10 · see citing works

Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-β 3-42 (pE 3 -Aβ)

Mehta, P. D., Patrick, B. A., Barshatzky, M., Mehta, S. P., Frackowiak, J., Mazur‐Kolecka, B., Węgiel, J., Wısnıewskı, T., & Miller, D. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170898 · Cited by 10 · see citing works

Tg-SwDI transgenic mice: A suitable model for Alzheimer's disease and cerebral amyloid angiopathy basic research and preclinical studies

Rodríguez-López, A., Esteban, D., Domínguez‐Romero, A. N., & Gevorkian, G. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115189 · Cited by 9 · see citing works

Active Aβ vaccination fails to enhance amyloid clearance in a mouse model of Alzheimer's disease with Aβ42-driven pathology

Nemirovsky, A., Shapiro, J., Baron, R., Kompaniets, A., & Monsonego, A. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.03.017 · Cited by 9 · see citing works

Aβ oligomer eliminating compounds interfere successfully with pEAβ(3–42) induced motor neurodegenerative phenotype in transgenic mice

Dunkelmann, T., Teichmann, K., Ziehm, T., Schemmert, S., Frenzel, D., Tusche, M., Dammers, C., Jürgens, D., Langen, K., Demuth, H., et al. (2017) · Neuropeptides · doi:10.1016/j.npep.2017.11.011 · Cited by 9 · see citing works

Novel monoclonal antibody 3B8 specifically recognizes pyroglutamate-modified amyloid β 3-42 peptide in brain of AD patients and 3xTg-AD transgenic mice

Acero, G., Garay-Canales, C. A., Venegas, D., Ortega, E., & Gevorkian, G. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134876 · Cited by 9 · see citing works

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease

Zagorski, K., King, O., Hovakimyan, A., Petrushina, I., Antonyan, T., Chailyan, G., Ghazaryan, M., Hyrc, K. L., Chadarevian, J. P., Davtyan, H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24129797 · Cited by 8 · see citing works

Pyroglutamate-Amyloid-β and Glutaminyl Cyclase Are Colocalized with Amyloid-β in Secretory Vesicles and Undergo Activity-Dependent, Regulated Secretion

Cynis, H., Funkelstein, L., Toneff, T., Mosier, C., Ziegler, M. G., Koch, B., Demuth, H., & HOOK, V. Y. H. (2014) · Neurodegenerative Diseases · doi:10.1159/000358430 · Cited by 8 · see citing works

Flexible N‐Termini of Amyloid β‐Protein Oligomers: A Link between Structure and Activity?

Urbanc, B. (2017) · Israel Journal of Chemistry · doi:10.1002/ijch.201600097 · Cited by 8 · see citing works

Relationship between efficacy and preferential targeting of soluble Aβ aggregates

Kaplan, J. M., Gibbs, E., Coutts, J. A., Zhao, B., Mackenzie, I. R., Plotkin, S. S., & Cashman, N. R. (2025) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70184 · Cited by 6 · see citing works

Verstärkte Fibrillen‐Fragmentierung N‐terminal verkürzter, Pyroglutamat‐modifizierter Aβ‐Peptide

Wulff, M., Baumann, M., Thümmler, A., Yadav, J. K., Heinrich, L., Knüpfer, U., Schlenzig, D., Schierhorn, A., Rahfeld, J., Horn, U., et al. (2016) · Angewandte Chemie · doi:10.1002/ange.201511099 · Cited by 6 · see citing works

Synthesis and Evaluation of a Novel PET Radioligand for Imaging Glutaminyl Cyclase Activity as a Biomarker for Detecting Alzheimer’s Disease

Behof, W. J., Haynes, J. R., Whitmore, C. A., Cheung, Y., Tantawy, M. N., Peterson, T. E., Wijesinghe, P., Matsubara, J. A., & Pham, W. N. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00313 · Cited by 6 · see citing works

Increased TSPO expression, pyroglutamate-modified amyloid beta (AβN3(pE)) accumulation and transient clustering of microglia in the thalamus of Tg-SwDI mice

Rodríguez-López, A., Torres-Paniagua, A. M., Acero, G., Díaz, G., & Gevorkian, G. (2023) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2023.578150 · Cited by 6 · see citing works

A simplified and sensitive immunoprecipitation mass spectrometry protocol for the analysis of amyloid-beta peptides in brain tissue

Richard, B. C., Bayer, T. A., Lind, S. B., Shevchenko, G., & Bergquist, J. (2019) · Clinical mass spectrometry · doi:10.1016/j.clinms.2019.07.001 · Cited by 6 · see citing works

A Multifunctional Biocompatible Drug Candidate is Highly Effective in Delaying Pathological Signs of Alzheimer’s Disease in 5XFAD Mice

Segal‐Gavish, H., Danino, O., Barhum, Y., Ben‐Zur, T., Shai, E., Varon, D., Offen, D., & Fischer, B. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161236 · Cited by 6 · see citing works

Vulnerability of Spatial Pattern Separation in 5xFAD Alzheimer’s Disease Mouse Model

Gephine, L., Roux, C. M., Fréret, T., Boulouard, M., & Léger, M. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-231112 · Cited by 5 · see citing works

Immunotherapy Against N-Truncated Amyloid-β Oligomers

Bayer, T. A., & Wirths, O. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3560-4_3 · Cited by 4 · see citing works

Stealth Attack: Plaque-Specific Antibody Allows for Efficient Aβ Removal without Side Effects

Roh, J. H., & Holtzman, D. M. (2012) · Neuron · doi:10.1016/j.neuron.2012.11.018 · Cited by 3 · see citing works

Alzheimer’s disease vaccines: promises and pitfalls

Tabira, T. (2011) · Clinical Investigation · doi:10.4155/cli.11.71 · Cited by 2 · see citing works

The Study of Cognitive-Stimulating Activity of Fluorinated Tetrahydrocarbazole Derivatives and Behavioral Responses in Transgenic Tg6799 Mice with Alzheimer’s Disease

Nikolaeva, N. S., Maltsev, A. V., Овчинников, Р. К., Sokolov, V. B., Aksinenko, A. Y., Bovina, E. V., & Kinzirsky, A. S. (2019) · Biology Bulletin · doi:10.1134/s1062359019030075 · Cited by 2 · see citing works

Active immunization with bacteriophage AP205 VLPs results in reduced amyloid load and microgliosis in 5xFAD female mice

Piļipenko, V., Lieknina, I., Skrastiņa, D., Aktas, S., Revina, B. L., Upīte, J., Jansone, B., & Tārs, K. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04739-y · Cited by 1 · see citing works

Amyloid β-protein oligomers and Alzheimer's

Hayden, E. Y., & Teplow, D. B. (2013) · Cited by 1 · see citing works

Immunotherapeutics for Neurological Disorders

Messer, A. C., MANLEY, K. M., & Lemere, C. A. (2014) · Wiley eBooks · doi:10.1002/9783527682423.ch40 · Cited by 1 · see citing works

Structural and Toxic Properties of Protein Aggregates: Towards a Molecular Understanding of Alzheimer's Disease

Wang, L., & Campioni, S. (2011) · InTech eBooks · doi:10.5772/20922

Biophysical Analysis of the Structure and Aggregation of Amyloid beta Peptide

Abedin, F. (2021) · Journal of International Crisis and Risk Communication Research

Imaging Alzheimer’s Disease Beyond Amyloid Plaques

Pham, W. N. (2025) · World Congress on Medical Physics and Biomedical Engineering, September 7 - 12, 2009, Munich, Germany · doi:10.1007/978-3-031-90194-2_1

Métalloprotéases matricielles et maladie d'Alzheimer : étude du rôle de MT1-MMP dans le métabolisme de l'APP/Aß

Py, N. A. (2014) · theses.fr (ABES) · doi:10.70675/76e6e222zc088z470cza0c6za5a23187870c

P4‐408: Therapeutic effect of passive immunisation with a monoclonal antibody against low molecular weight pyroglutamate oligomers in a preclinical Alzheimer mouse model

Bayer, T. A., & Wirths, O. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.09.222

Oligomeric Pyroglutamate Amyloid-β is Present in Microglia and a Subfraction of Vessels in Patients with Alzheimer's Disease: Implications for Immunotherapy

Wirths, O., Hillmann, A., Pradier, L., Härtig, W., & Bayer, T. A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121945 · Cited by 21 · see citing works

Antibody 9D5 Recognizes Oligomeric Pyroglutamate Amyloid-β in a Fraction of Amyloid-β Deposits in Alzheimer's Disease without Cross-Reactivity with other Protein Aggregates

Venkataramani, V., Wirths, O., Budka, H., Härtig, W., Kovács, G. G., & Bayer, T. A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111379 · Cited by 17 · see citing works

Intraneuronal Aβ as a trigger for neuron loss: can this be translated into human pathology?

Bayer, T. A., & Wirths, O. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390857 · Cited by 41 · see citing works

Generation and Partial Characterization of Rabbit Monoclonal Antibody to Pyroglutamate Amyloid-β 3-42 (pE 3 -Aβ)

Mehta, P. D., Patrick, B. A., Barshatzky, M., Mehta, S. P., Frackowiak, J., Mazur‐Kolecka, B., Węgiel, J., Wısnıewskı, T., & Miller, D. L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170898 · Cited by 10 · see citing works